Overview

A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A double-blind placebo controlled randomized Phase 2 study to determine if JKB-122 compared with placebo resolves NASH on liver biopsy and improves fibrosis
Phase:
Phase 2
Details
Lead Sponsor:
TaiwanJ Pharmaceuticals Co., Ltd